secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001619856-25-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences reports Q3 2025 clinical data: vispa-cel 86% ORR, CB-011 92% ORR; cash $159.2M
--------------------------------------------------------------------------------

- Vispa-cel ANTLER phase 1: 86% ORR, 63% CR, 53% PFS at 12mo in 35 patients with optimized profile (≥2 HLA match, young donor).
- CB-011 CaMMouflage phase 1: 92% ORR, 75% ≥CR, 91% MRD-negativity in 12 BCMA-naïve patients at recommended dose.
- Cash, equivalents, and marketable securities $159.2M as of Sep 30, 2025; expected to fund operations into 2H 2027.
- Q3 2025 revenue $2.2M (vs $2.0M Q3 2024); R&D expenses $22.4M (down from $30.4M); G&A $9.2M (down from $9.8M).
- FDA recommends randomized controlled trial for vispa-cel pivotal phase 3 in 2L LBCL; company to refine design with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/0001619856-25-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/crbu-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer